|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/09/21 Y-mAbs Therapeutics, Inc. 10-Q 6/30/21 76:7.2M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.24M
2: EX-31.1 Certification -- §302 - SOA'02 HTML 28K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 27K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 23K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 23K
12: R1 Document and Entity Information HTML 75K
13: R2 Consolidated Balance Sheets HTML 98K
14: R3 Consolidated Balance Sheets (Parenthetical) HTML 34K
15: R4 Consolidated Statements of Net Income/(Loss) and HTML 87K
Comprehensive Income/(Loss)
16: R5 Consolidated Statements of Changes in HTML 82K
Stockholders' Equity
17: R6 Consolidated Statements of Cash Flows HTML 87K
18: R7 Organization and Description of Business HTML 24K
19: R8 Basis of Presentation HTML 29K
20: R9 Summary of Significant Accounting Policies HTML 78K
21: R10 Product Revenue HTML 54K
22: R11 Net Loss Per Share HTML 54K
23: R12 Inventory HTML 38K
24: R13 Accrued Liabilities HTML 42K
25: R14 License Agreements and Commitments HTML 135K
26: R15 Stockholders' Equity HTML 30K
27: R16 Share-Based Compensation HTML 92K
28: R17 Related Party Transactions HTML 25K
29: R18 Income Taxes HTML 27K
30: R19 Other Benefits HTML 24K
31: R20 Gain From Sale of Priority Review Voucher HTML 25K
32: R21 Summary of Significant Accounting Policies HTML 105K
(Policies)
33: R22 Summary of Significant Accounting Policies HTML 59K
(Tables)
34: R23 Product Revenue (Tables) HTML 49K
35: R24 Net Loss Per Share (Tables) HTML 52K
36: R25 Inventory (Tables) HTML 39K
37: R26 Accrued Liabilities (Tables) HTML 41K
38: R27 License Agreements and Commitments (Tables) HTML 129K
39: R28 Share-Based Compensation (Tables) HTML 84K
40: R29 BASIS OF PRESENTATION - Accumulated deficit HTML 24K
(Details)
41: R30 BASIS OF PRESENTATION - Secondary public offering HTML 34K
(Details)
42: R31 BASIS OF PRESENTATION - Cash and cash equivalents HTML 24K
(Details)
43: R32 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 29K
Concentration of Credit Risk (Details)
44: R33 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair HTML 40K
Value Measurement (Details)
45: R34 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 44K
Revenue Recognition - License Revenue (Details)
46: R35 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 23K
Segment (Details)
47: R36 PRODUCT REVENUE - Discounts and Allowances HTML 58K
(Details)
48: R37 PRODUCT REVENUE - Concentrations (Details) HTML 33K
49: R38 NET LOSS PER SHARE - Basic and diluted (Details) HTML 47K
50: R39 NET LOSS PER SHARE - Anti-dilutive securities HTML 23K
(Details)
51: R40 Inventory (Details) HTML 28K
52: R41 Accrued Liabilities (Details) HTML 36K
53: R42 LICENSE AGREEMENTS AND COMMITMENTS - MSK, CD33 and HTML 65K
MabVax License Agreement (Details)
54: R43 LICENSE AGREEMENTS AND COMMITMENTS - Other HTML 40K
agreements (Details)
55: R44 LICENSE AGREEMENTS AND COMMITMENTS - Lease HTML 60K
agreements (Details)
56: R45 LICENSE AGREEMENTS AND COMMITMENTS - Lease costs HTML 31K
(Details)
57: R46 LICENSE AGREEMENTS AND COMMITMENTS - Lease HTML 38K
maturities (Details)
58: R47 LICENSE AGREEMENTS AND COMMITMENTS - Lease term HTML 26K
and discount rate (Details)
59: R48 STOCKHOLDERS' EQUITY - Authorized, Common and HTML 40K
Preferred Stock (Details)
60: R49 STOCKHOLDERS' EQUITY - Stock grant agreements with HTML 79K
non-employees (Details)
61: R50 STOCKHOLDERS' EQUITY - Issuance of common stock HTML 38K
(Details)
62: R51 SHARE-BASED COMPENSATION - 2015 Plan (Details) HTML 31K
63: R52 SHARE-BASED COMPENSATION - 2018 Plan (Details) HTML 41K
64: R53 SHARE-BASED COMPENSATION - Stock option expense HTML 34K
(Details)
65: R54 SHARE-BASED COMPENSATION - Stock option activity HTML 64K
(Details)
66: R55 SHARE-BASED COMPENSATION - Stock option HTML 28K
unrecognized compensation (Details)
67: R56 SHARE-BASED COMPENSATION - Restricted Stock Unit HTML 62K
Activity (Details)
68: R57 Related Party Transactions (Details) HTML 35K
69: R58 INCOME TAXES - Expense (Details) HTML 35K
70: R59 INCOME TAXES - Uncertain tax positions (Details) HTML 23K
71: R60 Other Benefits (Details) HTML 29K
72: R61 Gain From Sale of Priority Review Voucher HTML 34K
(Details)
74: XML IDEA XML File -- Filing Summary XML 135K
11: XML XBRL Instance -- ymab-20210630x10q_htm XML 1.59M
73: EXCEL IDEA Workbook of Financial Reports XLSX 85K
7: EX-101.CAL XBRL Calculations -- ymab-20210630_cal XML 130K
8: EX-101.DEF XBRL Definitions -- ymab-20210630_def XML 488K
9: EX-101.LAB XBRL Labels -- ymab-20210630_lab XML 1.13M
10: EX-101.PRE XBRL Presentations -- ymab-20210630_pre XML 847K
6: EX-101.SCH XBRL Schema -- ymab-20210630 XSD 162K
75: JSON XBRL Instance as JSON Data -- MetaLinks 325± 478K
76: ZIP XBRL Zipped Folder -- 0001558370-21-010959-xbrl Zip 297K
 | Download this zipped .zip folder |
| Files: | ymab-20210630.xsd ymab-20210630_cal.xml ymab-20210630_def.xml ymab-20210630_lab.xml ymab-20210630_pre.xml ymab-20210630x10q.htm ymab-20210630xex31d1.htm ymab-20210630xex31d2.htm ymab-20210630xex32d1.htm ymab-20210630xex32d2.htm |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/06/21 Y-mAbs Therapeutics, Inc. 10-Q 3/31/21 76:6.3M Toppan Merrill Bridge/FA 11/05/20 Y-mAbs Therapeutics, Inc. 10-Q 9/30/20 68:6.7M Toppan Merrill Bridge/FA 9/26/18 Y-mAbs Therapeutics, Inc. 8-K:5,7,9 9/25/18 4:284K Toppan Merrill/FA 8/24/18 Y-mAbs Therapeutics, Inc. S-1 31:12M Toppan Merrill-FA |